within Pharmacolibrary.Drugs.ATC.A;

model A10AE06
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5e-07,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00474,
    k12             = 0.059,
    k21             = 0.059
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10AE06</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Insulin degludec is a long-acting human insulin analog used in the management of diabetes mellitus in adults, adolescents, and children aged 1 year and above. It is approved for once-daily subcutaneous administration and achieves a flat and stable pharmacokinetic profile, allowing for flexible dosing intervals.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects with type 1 and type 2 diabetes after subcutaneous administration.</p><h4>References</h4><ol><li><p>Mathiesen, ER, et al., &amp; Damm, P (2023). Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial. <i>The lancet. Diabetes &amp; endocrinology</i> 11(2) 86–95. DOI:<a href=&quot;https://doi.org/10.1016/S2213-8587(22)00307-2&quot;>10.1016/S2213-8587(22)00307-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36623517/&quot;>https://pubmed.ncbi.nlm.nih.gov/36623517</a></p></li><li><p>Kiss, I, et al., &amp; Haahr, H (2014). Insulin degludec: pharmacokinetics in patients with renal impairment. <i>Clinical pharmacokinetics</i> 53(2) 175–183. DOI:<a href=&quot;https://doi.org/10.1007/s40262-013-0113-2&quot;>10.1007/s40262-013-0113-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24163264/&quot;>https://pubmed.ncbi.nlm.nih.gov/24163264</a></p></li><li><p>Scheen, AJ, &amp; Mathieu, C (2019). [Basal insulin degludec (Tresiba®)]. <i>Revue medicale de Liege</i> 74(4) 226–232. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30997973/&quot;>https://pubmed.ncbi.nlm.nih.gov/30997973</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10AE06;
